Possibly specific immune complexes in sera of patients with untreated acute myelogenous leukemia
✍ Scribed by R. Fäldt; J. Ankerst
- Publisher
- John Wiley and Sons
- Year
- 1980
- Tongue
- French
- Weight
- 470 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Eleven patients with acute myelogenous leukemia (AML) in the acute stage of the disease were studied. Sera of seven patients were assayed for complement‐dependent cytotoxicity to autochthonous AML cells and sera of four patients were tested with allogeneic target cells before and after ultrafiltration at low pH. No specific cytotoxic activity could be detected in any untreated sera. Ultrafiltration at low pH led, however, to the appearance of a significant cytotoxic activity in all of seven autochthonous and in three of four allogeneic combinations. Identical treatment of control AB sera did not result in any similar activity. The results show that potentially cytotoxic antibodies to leukemia‐associated antigens are present in the acute stage of acute myelogenous leukemia. However, they do not express complement‐dependent cytotoxicity in untreated sera. After ultrafiltration at low pH significant complement‐dependent cytotoxicity was detectable in most of the sera. One possible explanation is that cytotoxic antibodies to leukemia‐associated antigens are present in the form of circulating immune complexes. Splitting of them at low pH and elimination of the antigen component might result in an increased amount of free cytotoxic antibodies.
📜 SIMILAR VOLUMES
## Abstract Gemtuzumab ozogamicin (GO; CMA‐676; Mylotarg™) is a chemotherapeutic agent approved for the treatment of CD33‐positive acute myelogenous leukemia in patients of age 60 years or older after first relapse. Hepatic veno‐occlusive disease has been reported to develop as a late complication
## Abstract To understand the effect of dose concentration in the overall survival of AML, we conducted a study on the efficacy and toxicity of a drug combination where the dose of daunorubicin was intensified. For this analysis, the outcome of patients entered into two consecutive prospective tria
Lymphatic filarial subjects with disease manifestations exhibit significantly elevated levels of immune complexes (ICs) in their circulation. The objective of the study was to explore the possible excretion of filariaspecific soluble ICs in urine of subjects with lymphatic filariasis. Paired urine (